# Taro renews bid to block state AGs' price-fixing claims via $200M MDL deal

Attorney advertising. Brief by Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. Published 2026-11-18; updated 2026-11-18. Responsible attorney: Lou Schwartz. Canonical: https://www.snalawyers.com/insights/taro-renews-bid-to-block-state-ags-price-fixing-claims-via-200m-mdl-de

Taro Pharmaceuticals told a Connecticut federal judge on November 18, 2026 that its $200 million settlement with end-payer plaintiffs in the generic-drug price-fixing MDL should bar a separate set of consumer price-fixing claims brought by dozens of state attorneys general. The dispute arises in the long-running In re Generic Pharmaceuticals Pricing Antitrust Litigation, where state enforcers have argued their claims and plaintiffs are too distinct from the MDL class to be bound by Taro's settlement.

**Why it matters.** The outcome will determine whether consumers harmed by alleged generic-drug price-fixing can pursue recovery through state AG enforcement actions even after a drugmaker has settled parallel private claims, a question relevant to other multi-track price-fixing recoveries the firm tracks.

## Sources

1. [Law360](https://www.law360.com/compliance/articles/2551714)

To ask the firm about this, use the intake assistant at https://www.snalawyers.com/insights/taro-renews-bid-to-block-state-ags-price-fixing-claims-via-200m-mdl-de#ask. General information, not legal advice.
